Sugemalimab with chemotherapy for advanced ESCC

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2024-02-14 DOI:10.1038/s41575-024-00912-5

Katrina Ray

引用次数: 0

查看原文本刊更多论文

苏格玛单抗联合化疗治疗晚期 ESCC

一项多中心、随机、双盲、III 期试验报告了舒格马单抗（一种 PDL1 抗体）联合化疗治疗晚期食管鳞状细胞癌 (ESCC) 的积极结果。共有540名患有不可切除、局部晚期、复发或转移性ESCC且之前未接受过系统治疗的成人（18-75岁）以2:1的比例被随机分配到接受1,200毫克苏格玛单抗或安慰剂，外加每3周一次的化疗（顺铂加5-氟尿嘧啶），最多6个周期。该研究在预设的中期分析中达到了两个主要终点。与安慰剂相比，苏格玛单抗联合化疗可显著延长晚期ESCC免疫治疗患者的无进展生存期（中位6.2个月对5.4个月，HR 0.67（95% CI 0.54-0.82）；P = 0.0002）和总生存期（中位15.3个月对11.5个月，HR 0.70（95% CI 0.44-0.90）；P = 0.0076）。两组患者的3级或以上治疗相关不良事件发生率相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.

文献相关原料

公司名称	产品信息	采购帮参考价格